IMRX

Immuneering Corp. Class A Common Stock (IMRX) | Rumor.io

Immuneering

IMRX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,742

Bullish sentiment (50-day avg)74%

Price to earnings ratio-3.28

Market capitalization269.1M

Earnings per share-0.93

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-56M

Social

What share of all stock conversation is about IMRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 12

IMRX's short interest is 60.3% of the free float, with 6.0% of shares available for borrowing.
Analysts see a medium-term outlook favoring a measured advance that could challenge the double-digit zone.
Immuneering Corporation's lead oncology candidate, atebimetinib, is advancing toward a potential registrational study in first-line metastatic pancreatic cancer.

Generated by AI

Sentiment

Of the messages about IMRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +23.33	87.11% +0.16
Bearish	—	—	0% -23.33	12.89% -0.16

Bullish· Jun 1

The company's Phase 3 study is expected to start in 30-60 days, indicating a promising near-term outlook.
Immuneering Corporation has a strong cash position, with a cash runway into 2029, providing a buffer for the company's growth.
The company's data is supportive of its ongoing Phase 3 study, with patients experiencing improved outcomes and reduced side effects, indicating a positive long-term trend.

Bearish· Jun 2

The company's stock price has been manipulated by market makers, leading to a decline in value.
The recent news of a pancreatic cancer drug with 17.3 months survival rate has not been enough to move the stock price, suggesting a lack of investor confidence.
The stock's valuation is considered ridiculous, and some investors believe it may drop below $3 due to the upcoming summer doldrums and tax loss selling.

Generated by AI

Topics

Of the messages about IMRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	92.59%	58.32%
Analysts	—	0%	0%	22.73%
Controversies	—	0%	0%	0.93%
Technical Analysis	—	0%	7.41%	8.88%
Earnings	—	0%	0%	2.17%
Macro	—	0%	0%	6.96%

Announcements· Jan 9

*Immuneering Corporation (IMRX) files Form 8-K: Other Events, impacting the market with a -43.22% drop to $4.73 on January 7, 2026.
*A shift from 1.6x to 2.5x sales multiple implies a potential $135M upside for NextNRG Inc. (NXXT), a company closely associated with IMRX.
*Regulatory progress tends to shift valuation frameworks quickly, with Mainz Biomed N.V. being set up for such a shift, and IMRX being mentioned as a related company.

Technical Analysis· Jan 7

IMRX has shown strong momentum, with a 1000% increase in price on a particular day due to a news catalyst, and has been identified as a momentum stock with high relative volume.
Technical analysis indicates that IMRX is in a strong uptrend, with multiple touches expected on a key resistance level of $5 before a breakout or reversal, and extension targets of 3.85 and 4.40-50.
IMRX has formed clear demand and supply levels, with a potential breakout level at $2.47, and has been identified as a stock to watch with promising bullish momentum and a key breakout level at $2.47.

Generated by AI

Community

Of the messages about IMRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	91.34%	45.57%
Newcomers	—	0%	8.66%	54.43%

Regulars· Jun 1

The updated clinical data from Immuneering's Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) showed a 17.3-month median overall survival, doubling the 8.5-month median overall survival of the standard of care treatment.
The new data presented at ASCO 2026 appears to be a major catalyst for Immuneering's stock, with some participants expressing skepticism about the market's reaction to the compelling results.
The selloff of Immuneering's stock may be driven by the fact that the majority of offerings have been followed by a decline in the company's share price, with some professional funds wondering why Immuneering's stock has been grinding up despite this trend.

Newcomers· May 22

Newcomers are excited about Immuneering Corporation's ($IMRX) oncology drug pipeline and clinical-stage potential, with some investors focusing on its lead candidate, atebimetinib (IMM-1-104), which targets the RAS/MAPK pathway.
Many are paying attention to $IMRX's recent surge in stock price after positive pancreatic cancer survival data was presented, with some considering it a late-stage biopharmaceutical company focused on oncology.
Some investors are taking profits on $IMRX, but with a strong cash position and runway into 2029, the company is seen as having time to push its platform and potentially deliver further catalysts.

Generated by AI

News

Immuneering at H.C. Wainwright conference: pancreatic cancer push

15d agoInvesting.com

Immuneering at cantor healthcare conference: pancreatic cancer bet gains focus

19d agoInvesting.com

Immuneering to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences: Cantor Global Healthcare Conference (September 9-11 in New York City) Format: Fireside Chat and 1x1 Investor MeetingsDate/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET H.C. Wainwright 28th Annual Gl

26d agoYahoo Finance

H.C. Wainwright reiterates Immuneering stock rating on MEK pathway potential

1mo agoInvesting.com

Immuneering comments on FDA pancreatic cancer drug approval

1mo agoInvesting.com

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

1mo agoBarchart.com

Also Discussed

Investors talking about IMRX also mention

#	Name	Attention
1	Revolution Medicines, Inc.RVMD	0.01%-0.01
2	Erasca Inc.ERAS	0%0
3	Tharimmune Inc.THAR	0%new
4	BG Staffing IncBGSF	0%new
5	OMIC - Singular Genomics Systems, Inc.	——
6	Sera Prognostics, Inc. Class A Common StockSERA	0%0
7	Mega Matrix Inc.MPU	0%0
8	Elicio Therapeutics Inc.ELTX	0%0
9	IO Biotech, Inc.IOBT	0%0
10	AIFU Inc. Class A Ordinary ShareAIFU	0%+0

Immuneering Corp. Class A Common Stock

Healthcare
Biotechnology

Immuneering Corp. Class A Common Stock represents ownership in Immuneering Corporation, a clinical-stage oncology company focused on developing medicines for broad populations of cancer patients. Immuneering’s current work centers on a pipeline of drug candidates designed to address cancer through its computational drug discovery approach, including lead programs aimed at solid tumors and mutations associated with difficult-to-treat cancers. The company’s research platform supports the identification and development of therapies built to interfere with cellular signaling pathways, with an emphasis on oncology applications. Immuneering also operates in computational biology and translational bioinformatics, applying its scientific platform to advance drug discovery activities. Headquartered in Cambridge, Massachusetts, Immuneering Corporation serves the biotechnology and pharmaceutical sectors through its ongoing clinical development programs and research-driven approach to cancer medicine.

Website

Location

245 Main Street

Cambridge, MA, 02142

United States

Social

What share of all stock conversation is about IMRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Aug 12

IMRX's short interest is 60.3% of the free float, with 6.0% of shares available for borrowing.
Analysts see a medium-term outlook favoring a measured advance that could challenge the double-digit zone.
Immuneering Corporation's lead oncology candidate, atebimetinib, is advancing toward a potential registrational study in first-line metastatic pancreatic cancer.

Generated by AI

Sentiment

Of the messages about IMRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +23.33	87.11% +0.16
Bearish	—	—	0% -23.33	12.89% -0.16

Bullish· Jun 1

The company's Phase 3 study is expected to start in 30-60 days, indicating a promising near-term outlook.
Immuneering Corporation has a strong cash position, with a cash runway into 2029, providing a buffer for the company's growth.
The company's data is supportive of its ongoing Phase 3 study, with patients experiencing improved outcomes and reduced side effects, indicating a positive long-term trend.

Bearish· Jun 2

The company's stock price has been manipulated by market makers, leading to a decline in value.
The recent news of a pancreatic cancer drug with 17.3 months survival rate has not been enough to move the stock price, suggesting a lack of investor confidence.
The stock's valuation is considered ridiculous, and some investors believe it may drop below $3 due to the upcoming summer doldrums and tax loss selling.

Generated by AI

Topics

Of the messages about IMRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	92.59%	58.32%
Analysts	—	0%	0%	22.73%
Controversies	—	0%	0%	0.93%
Technical Analysis	—	0%	7.41%	8.88%
Earnings	—	0%	0%	2.17%
Macro	—	0%	0%	6.96%

Announcements· Jan 9

*Immuneering Corporation (IMRX) files Form 8-K: Other Events, impacting the market with a -43.22% drop to $4.73 on January 7, 2026.
*A shift from 1.6x to 2.5x sales multiple implies a potential $135M upside for NextNRG Inc. (NXXT), a company closely associated with IMRX.
*Regulatory progress tends to shift valuation frameworks quickly, with Mainz Biomed N.V. being set up for such a shift, and IMRX being mentioned as a related company.

Technical Analysis· Jan 7

IMRX has shown strong momentum, with a 1000% increase in price on a particular day due to a news catalyst, and has been identified as a momentum stock with high relative volume.
Technical analysis indicates that IMRX is in a strong uptrend, with multiple touches expected on a key resistance level of $5 before a breakout or reversal, and extension targets of 3.85 and 4.40-50.
IMRX has formed clear demand and supply levels, with a potential breakout level at $2.47, and has been identified as a stock to watch with promising bullish momentum and a key breakout level at $2.47.

Generated by AI

Community

Of the messages about IMRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	91.34%	45.57%
Newcomers	—	0%	8.66%	54.43%

Regulars· Jun 1

The updated clinical data from Immuneering's Phase 2a trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC) showed a 17.3-month median overall survival, doubling the 8.5-month median overall survival of the standard of care treatment.
The new data presented at ASCO 2026 appears to be a major catalyst for Immuneering's stock, with some participants expressing skepticism about the market's reaction to the compelling results.
The selloff of Immuneering's stock may be driven by the fact that the majority of offerings have been followed by a decline in the company's share price, with some professional funds wondering why Immuneering's stock has been grinding up despite this trend.

Newcomers· May 22

Newcomers are excited about Immuneering Corporation's ($IMRX) oncology drug pipeline and clinical-stage potential, with some investors focusing on its lead candidate, atebimetinib (IMM-1-104), which targets the RAS/MAPK pathway.
Many are paying attention to $IMRX's recent surge in stock price after positive pancreatic cancer survival data was presented, with some considering it a late-stage biopharmaceutical company focused on oncology.
Some investors are taking profits on $IMRX, but with a strong cash position and runway into 2029, the company is seen as having time to push its platform and potentially deliver further catalysts.

Generated by AI

Immuneering

Social

Aug 12

Bullish· Jun 1

Bearish· Jun 2

Announcements· Jan 9

Technical Analysis· Jan 7

Regulars· Jun 1

Newcomers· May 22

Immuneering at H.C. Wainwright conference: pancreatic cancer push

Immuneering at cantor healthcare conference: pancreatic cancer bet gains focus

Immuneering to Participate in Upcoming Investor Conferences

H.C. Wainwright reiterates Immuneering stock rating on MEK pathway potential

Immuneering comments on FDA pancreatic cancer drug approval

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Also Discussed

Immuneering Corp. Class A Common Stock

Company Information

Location

Immuneering at H.C. Wainwright conference: pancreatic cancer push

Immuneering at cantor healthcare conference: pancreatic cancer bet gains focus

Immuneering to Participate in Upcoming Investor Conferences

H.C. Wainwright reiterates Immuneering stock rating on MEK pathway potential

Immuneering comments on FDA pancreatic cancer drug approval

Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients

Also Discussed

Social

Aug 12

Bullish· Jun 1

Bearish· Jun 2

Announcements· Jan 9

Technical Analysis· Jan 7

Regulars· Jun 1

Newcomers· May 22